Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,065 across all filing types
Latest filing 2025-09-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
君实生物H股公告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 中期報告' which translates to '2025 Interim Report'. It contains detailed financial data for the six months ended June 30, 2025, including income, expenses, losses, and balance sheet items. It also includes management discussion and analysis (MD&A) sections, business overview, product pipeline, clinical trial updates, and operational details. The document is comprehensive, with over 15,000 characters, and includes actual financial statements and substantive financial analysis. It is not merely an announcement or a certification. The content and structure clearly identify it as an Interim / Quarterly Report (IR). H1 2025
2025-09-28 Chinese
君实生物监事会关于公司2025年A股股票期权激励计划首次授予激励对象名单的公示情况说明及核查意见
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board of Shanghai Junshi Biosciences regarding the initial grant list of incentive recipients under the company's 2025 A-share stock option incentive plan. It details the supervisory board's verification and confirmation of the eligibility and qualifications of the incentive recipients according to relevant laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement related to stock option incentive plan participants and their verification by the supervisory board. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about stock option incentive plan verification and public notice, not a full report or financial document.
2025-09-22 Chinese
君实生物2025年第一次临时股东大会会议资料（更新版）
AGM Information Classification · 95% confidence The document is titled as the "2025 First Extraordinary General Meeting (EGM) Meeting Materials" of Shanghai Junshi Biosciences Co., Ltd. It contains detailed meeting agenda, proposals for shareholder approval including election of independent non-executive directors, amendments to internal management systems, capital changes, and stock option incentive plans. The content is typical of materials prepared and distributed for a shareholders' meeting to inform and solicit votes on various corporate governance and capital matters. It is not a report of financial results, audit, or earnings, nor is it a transcript or announcement of voting results. The document is comprehensive and lengthy (15,000 characters), consistent with meeting materials rather than a brief announcement. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2025-09-15 Chinese
君实生物关于2025年第一次临时股东大会增加临时提案暨延期召开的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the addition of temporary proposals and the postponement of the 2025 first extraordinary general meeting (临时股东大会) of Shanghai Junshi Biosciences Co., Ltd. It details the meeting date change, the new proposals to be considered, voting procedures, and proxy forms. There are no financial statements or detailed financial data presented. The document is primarily about the organization and agenda of a shareholders' meeting, specifically an extraordinary general meeting (EGM). It is not the meeting materials themselves, nor the voting results, but an announcement about changes to the meeting agenda and schedule. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like AGM Information or Declaration of Voting Results.
2025-09-15 Chinese
君实生物关于持股5%以上股东权益变动触及1%刻度的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about changes in shareholding percentages by shareholders holding more than 5% of the company's shares. It details the decrease in shareholding percentages, the parties involved, and confirms that the change does not trigger mandatory tender offers or control changes. The document is titled as a "提示性公告" (prompting announcement) regarding shareholding changes touching the 1% threshold. It does not contain financial statements or detailed financial analysis but is a formal announcement of a major shareholding change. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 2246 characters, which is consistent with a notification rather than a full report.
2025-09-12 Chinese
君实生物自愿披露关于抗IL-17A单抗治疗中重度斑块状银屑病的Ⅲ期临床研究达到主要研究终点的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shanghai Junshi Biosciences regarding positive results from a Phase III clinical trial of their IL-17A monoclonal antibody treatment for moderate to severe plaque psoriasis. It details the clinical study design, results, and future plans to submit for regulatory approval. The document is an announcement of clinical trial progress and results, not a financial report, regulatory filing, or management report. It does not contain financial statements or detailed financial analysis. It is also not a report publication announcement since it provides substantive information about the clinical trial outcome. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about clinical trial results and company progress that does not fit other specific categories.
2025-09-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.